Stockscreener 앱 받기
0.5041
28.30%
0.1112
시장 영업 전:
.43
-0.0741
-14.70%
전일 마감가:
$0.3929
열려 있는:
$0.5997
하루 거래량:
93.73M
Relative Volume:
29.69
시가총액:
$92.20M
수익:
$9.10M
순이익/손실:
$-82.47M
주가수익비율:
-0.8691
EPS:
-0.58
순현금흐름:
$-72.32M
1주 성능:
+24.78%
1개월 성능:
+20.14%
6개월 성능:
-17.78%
1년 성능:
-34.49%
1일 변동 폭
$0.491
$0.6213
1주일 범위
$0.3824
$0.6213
52주 변동 폭
$0.285
$1.07
Vaxart Inc Stock (VXRT) Company Profile
명칭
Vaxart Inc
전화
(650) 550-3500
주소
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
VXRT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.5041 | 92.20M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-15 | 개시 | Oppenheimer | Outperform |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-11-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-29 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-06-24 | 개시 | Jefferies | Buy |
| 2021-06-11 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
모두보기
Vaxart Inc 주식(VXRT)의 최신 뉴스
Vaxart soars on positive data from new norovirus vaccine trial - MSN
Vaxart (VXRT) Shares Soar After Promising Norovirus Vaccine Tria - GuruFocus
Vaxart's Oral Norovirus Vaccine Pills Meet Primary Immunological Endpoint in Phase 1 Trial - marketscreener.com
Sector Update: Health Care Stocks Higher Pre-Bell Wednesday - marketscreener.com
Vaxart stock soars after positive Phase 1 norovirus vaccine results - Investing.com
Vaxart (VXRT) Unveils Promising Phase 1 Results for New Norovirus Vaccine | VXRT Stock News - GuruFocus
Vaxart reports improved antibody response in norovirus vaccine trial - Investing.com Australia
Vaxart Reports Positive Clinical Data Demonstrating that its Sec - GuruFocus
Vaxart Reports Positive Clinical Data Demonstrating Second-Generation Vaccine Technology Produces Stronger Antibody Responses Than First-Generation - marketscreener.com
Vaxart Reports Positive Clinical Data Demonstrating that - GlobeNewswire
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology - Yahoo Finance
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial | VXRT Stock News - GuruFocus
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial - GlobeNewswire
Vaxart to Reveal First-Ever Oral Norovirus Vaccine Trial Results: Key Data Coming Tomorrow - Stock Titan
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 | VXRT Stock News - GuruFocus
Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart - Business Wire
Vaxart Announces Adjournment of Annual Meeting of Stockholders | - GuruFocus
Vaxart Announces Adjournment Of Annual Meeting Of Stockholders - marketscreener.com
Vaxart Announces Adjournment of Annual Meeting of Stockholders | VXRT Stock News - GuruFocus
Vaxart Annual Meeting Adjourned to June 13, 2025; Proxy Advisory Firms Support Proposal No. 2 - Nasdaq
Vaxart Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Vaxart Gets ISS and Glass Lewis Backing for Crucial Nasdaq Listing Vote as Deadline Nears - Stock Titan
Vaxart stock climbs on positive study of pill-based norovirus vaccine - MSN
Zoom Rises 8% in 3 Months: Here's Why You Should Buy the Stock Now - The Globe and Mail
Vaxart seeks shareholder nod for reverse stock split By Investing.com - Investing.com South Africa
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025 - The Manila Times
Vaxart Leaders Set for Key Fireside Chat at Major Healthcare Conference: What to Expect - Stock Titan
Vaxart (VXRT) Releases Video Update Urging Support for Reverse S - GuruFocus
Vaxart seeks shareholder nod for reverse stock split - Investing.com Australia
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders | VXRT Stock News - GuruFocus
Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders - GlobeNewswire
Vaxart Founder Makes Urgent Appeal: Critical Nasdaq Compliance Vote Deadline Approaches - Stock Titan
Vaxart Discusses Reverse Stock Split and Capital Raise - TipRanks
Vaxart Answers Additional Frequently Asked Questions from Retail Investors - GlobeNewswire
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Mee - GuruFocus
Vaxart Begins Phase 2b Trial for Oral COVID-19 Vaccine - TipRanks
Vaxart (VXRT) Addresses Stockholder Concerns Ahead of Annual Meeting | VXRT Stock News - GuruFocus
Vaxart Reveals New Split Ratio Details as Nasdaq Delisting Deadline LoomsCEO Urges Action - Stock Titan
USDJPY Faces An Intraday Corrective Recovery: Elliott Wave Intraday Analysis - The Globe and Mail
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vacc - GuruFocus
Vaxart Initiates Dosing In 10,000-Participant Portion Of Phase 2B Covid-19 Trial - marketscreener.com
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial - GlobeNewswire
Vaxart (VXRT) Advances in Phase 2b Trial with Oral COVID-19 Vaccine | VXRT Stock News - GuruFocus
Breakthrough Oral COVID Vaccine Pill Advances: Vaxart Launches Massive 10,000-Patient Trial with $460M Backing - Stock Titan
RFK Jr issues bombshell order on Covid vaccine over safety concerns - MSN
Vaxart (NASDAQ:VXRT) Upgraded at Wall Street Zen - Defense World
Vaxart Urges Stockholder Action: Crucial Nasdaq Compliance Vote Delayed as Reverse Split Hangs in Balance - Stock Titan
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock News - GuruFocus
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart, Inc. Grants Equity Awards to New CFO Jeroen Grasman - Nasdaq
Vaxart Lures New CFO With Massive 1.35M Share Package: Inside the Compensation Deal - Stock Titan
Vaxart Inc (VXRT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.92%
7.75%
자본화:
|
볼륨(24시간):